Tonix shares sink 29% on discontinued development on depression treatment

Shares of Tonix Pharmaceuticals fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.